The Center for Biosimilars Staff

October 05, 2017

A new study comparing the clinical effectiveness of anti–tumor necrosis factor agents and the interleukin-6 inhibitor tocilizumab (Acterma) in patients with rheumatoid arthritis found that tocilizumab outperformed anti-TNFs in terms of effectiveness and drug survival.

October 03, 2017

Drug maker Shire has filed suit in a federal court in Newark, New Jersey, alleging that rival Allergan has violated antitrust laws in trying to preserve market share of its cyclosporine ophthalmic emulsion (Restasis) by blocking competition from Shire’s dry-eye drug, lifitegrast (Xiidra), on the Medicare Part D formulary.

October 02, 2017

If Roche is successful in securing FDA approval, use of pertuzumab together with trastuzumab (also developed by Genentech's parent company, Roche) could help the drug maker hold on to some of its oncology market dominance in the face of growing competition from anticancer biosimilars.

October 01, 2017

Where does the market for infliximab stand in the United States? Our infographic provides a brief history of Remicade and its biosimilars.

September 29, 2017

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of September 25, 2017.

September 29, 2017

The California legislature has passed SB 17, a major effort to ensure transparency in drug pricing.

September 27, 2017

The European Medicines Agency released results of an internal survey that asked staff to which proposed cities they would consider relocating. The lowest-ranking city was one to which only 6% of respondents were likely or very likely to relocate.

September 26, 2017

Republicans have cancelled plans to vote on the latest legislative effort to repeal and replace the Affordable Care Act after 3 members of the party announced that they would vote “no” on the Graham-Cassidy bill.

September 26, 2017

Biosimilar developer Hospira has been ordered to pay Amgen $70 million after a jury found that the drug maker infringed on Amgen’s US Patent Number 5,856,298 (the ‘298 patent), which covers erythropoietin.

September 26, 2017

Healthcare company Fresenius Kabi has initiated a $250 million expansion of its Illinois manufacturing location and acquired Merck KGaA's biosimilars business.